Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 8cyclopia sequence 6Prostatic Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Polycystic Ovary Syndrome 2Pancreatic Neoplasms 2Neoplasms, Plasma Cell 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Hematologic Diseases 2Head and Neck Neoplasms 2Fatigue 2Warts 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Intraepithelial Neoplasia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Papilloma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuromyelitis Optica 1Myelitis, Transverse 1Myelitis 1Melanoma 1

Interventions

Tamoxifen 12Specimen Handling 6Anastrozole 6Chemotherapy, Adjuvant 5Radiotherapy 4Letrozole 4afimoxifene 3Mastectomy, Segmental 3Surgical Procedures, Operative 2Simvastatin 2Radiation Dose Hypofractionation 2Radiation 2Fish Oils 2Fatty Acids, Omega-3 24,17 beta-dihydroxy-4-androstene-3-one 2telapristone acetate 1sargramostim 1ruxolitinib 1polyphenon E 1palbociclib 1fezolinetant 1exemestane 1elacestrant 1darolutamide 1bazedoxifene 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1abemaciclib 1Zoledronic Acid 1Testosterone 1Tea 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Intraductal, Noninfiltrating × Sugars × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡